CORDIS
EU research results

CORDIS

English EN
Development of a novel replication-deficient mucosal rna vaccine protecting against respiratory viral disease of early childhood

Development of a novel replication-deficient mucosal rna vaccine protecting against respiratory viral disease of early childhood

Objective

The aim of the project is the development and the pre-clinical evaluation of a mucosal RNA-based virosomal vaccine against respiratory diseases of the early childhood caused by human parainfluenzavirus type 3 and respiratory syncytial virus. Antigens are encoded on a Sendai virus RNA packaged in a nucleocapsid and encapsulated into immunostimulating reconstituted virosomes. For an excellent safety standard, the nucleocapsid is completely replication-deficient by deletion of the N gene. Antigen combinations are provided by a single vaccine formulation in a modular system. The vaccine will be applied in a one step process and the administration as a nasal spray allows an easy reapplication. This makes the new formulation economic, effective, safe and highly adaptable for vaccination of humans (also of animals) against various infectious diseases.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

Address

Am Klopferspitz 18 A
82152 Planegg / Krailling

Germany

Administrative Contact

F. Ulrich HARTL (Professor)

Participants (3)

Sort alphabetically

Expand all

BERNA BIOTECH LTD

Switzerland

NATIONAL UNIVERSITY OF IRELAND - MAYNOOTH

Ireland

UNIVERSIT DEGLI STUDI DI SIENA

Italy

Project information

Grant agreement ID: QLK2-CT-2002-01722

  • Start date

    1 October 2002

  • End date

    30 September 2006

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 1 757 302

  • EU contribution

    € 985 566

Coordinated by:

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

Germany